Cerus Corporation Interest Expense 2011-2026 | CERS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Cerus Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.98 M	1.76 M	-1.74 M	4.92 M	3.75 M	6.06 M	4.01 M	3.02 M	2.44 M	1.7 M	599 K	332 K	551 K	964 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
6.06 M	-1.74 M	2.17 M

Quarterly Interest Expense Cerus Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
976 K	845 K	606 K	604 K	412 K	452 K	233 K	2.18 M	1.61 M	-	1.41 M	1.35 M	1.38 M	-	1.28 M	1.34 M	972 K	-	930 K	929 K	935 K	-	1.03 M	1.15 M	2.92 M	-	1.05 M	958 K	915 K	-	1.09 M	501 K	531 K	-	586 K	658 K	655 K	-	505 K	301 K	255 K	-	249 K	34 K	50 K	-	41 K	107 K	131 K	-	136 K	135 K	139 K	-	394 K	220 K	233 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.92 M	34 K	743 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
ANI Pharmaceuticals ANIP	-4.03 M	$ 80.97	0.78 %	$ 1.56 B	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Amarin Corporation plc AMRN	8 K	$ 14.8	0.34 %	$ 6.03 B	Irlanda
I-Mab IMAB	722 K	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Adagene ADAG	1.11 M	$ 2.63	-1.5 %	$ 148 M	China
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.55	-0.56 %	$ 8.54 B	Australia
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 221.53	-0.23 %	$ 5 B	Danmark
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 4.55	6.29 %	$ 9.9 B	Israel
Autolus Therapeutics plc AUTL	9.29 M	$ 1.46	-0.1 %	$ 373 M	Britain
Amneal Pharmaceuticals AMRX	11.8 M	$ 14.52	-	$ 4.49 B	USA
Codexis CDXS	-10.4 M	$ 1.29	0.01 %	$ 94.7 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA